Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Xgeva TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: denosumab
Brand name
(ARTG)
: XGEVA denosumab (rch) 70mg/mL (120mg/1.7mL) solution for injection vialDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Prevention of skeletal related events in patients with multiple myeloma and in patients with bone metastases from solid tumours. Treatment of giant cell tumour of bone in adults or skeletally mature adolescents that is recurrent, or unresectable, or resectable but associated with severe morbidity. Treatment of hypercalcaemia of malignancy that is refractory to intravenous bisphosphonate.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Clear, colourless to slightly yellow solution
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from direct sunlight
- Do not Shake
- Shelf lifetime is 3 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 vial pack
- 4 vials pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient denosumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Top results
Risks and management for treating osteoporosis
Given the high prevalence of osteoporosis, many cases are likely to be undetected and undertreated.
Read more on Australian Prescriber website
Osteonecrosis of the jaw and denosumab
The risk of osteonecrosis of the jaw may be higher with denosumab than with bisphosphonates.
Read more on Australian Prescriber website
Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016 - Australasian Menopause Society
Osteoporosis is preventable and treatable, but only a small proportion of people at risk for fractures are evaluated and treated
Read more on Australasian Menopause Society website